Seres Product Name: Bromhexine Hydrochloride
Seres aliases: Bromhexine hydrochloride; Hydrochloride bromhexylamine; Benzylcyclohexylamine bromide hydrochloride; II-amino-3,5-Dibromo-n-cyclohefyl, n-methylbenzylamine hydrochloride; N- (II-amino-3,5-Dibromobenzyl) -n-Methylyclohexylamine hydrochloride;
Anglicus Product Name: Bromhexine HCL API
CAS # 611-75-6
Formula
Seres Product Name: Bromhexine Hydrochloride
Seres aliases: Bromhexine hydrochloride; Hydrochloride bromhexylamine; Benzylcyclohexylamine bromide hydrochloride; II-amino-3,5-Dibromo-n-cyclohefyl, n-methylbenzylamine hydrochloride; N- (II-amino-3,5-Dibromobenzyl) -n-Methylyclohexylamine hydrochloride;
Anglicus Product Name: Bromhexine HCL API
CAS # 611-75-6
M. Formula: C14H21BR2CLN2
M. pondus: 412.6
Et proprietatibus specie: Alba solidae
Domesticis Registration Number API: Y20170001111
Usus: usus est acuti et longos BRONCHITIS, suspiriosis, bronchiectasis, et emphysema. Praesertim idoneos qui difficultatem tussis alba glutinosus sputum et discrimine emergentia per extensive impedimentum parva bronchi sputum.
Bromhexine HCL API est ad respiratorii medicamento et tussim cum pituitam pharmacum.
Bromhexine Hcl API: A comprehensive Overview sua pharmacological et industriae significant
Introductio
Bromhexine Hydrochloride (Bromhexine HCL API) est mucolytic agente late agnita est ad efficaciam in administrandi perturbationes proprium est a nimia mucus productio. Sicut activae pharmaceutical ingredient (API), Bromhexine HCL est extensively studied et usus in formulationibus vndique ex ore tabulis ad syrups. Hoc articulum explorat multifaceted facies Bromhexine Hcl API, comprehendo eius pharmacological proprietatibus, synthesis, therapeutic applications, qualis imperium mensuras superiores et foro dynamics, underscoring in modern medicine.
Pharmacological mechanism
Bromhexine Hcl API exit eius medicinales effectus per Depolymerizing mucopolysaccharide fibris in bronchiales secretiones, ita redigo mucus viscositas et enhancing expelitione. Et compositis acts ut a secretolytic agente, stimulating productio de solo fluidi in tractu respiratorii, quae facilitates mucus alvi. Studiis demonstratum quod Bromhexine HCL API etiam auget penetratio antibiotics in pulmone TEXTUS, faciens illud adiungit adjunct in tractans bacterial respiratoriorum infectiones. Et dual action, mucolytic et antimicrobial synergy-positions quod est in angulari respiratorii Lorem.
Synthesis et vestibulum
Et synthesis de Bromhexine HCL API involves a multi-gradus eget processus incipiens a precursor compositis Vasicine, naturalis alkaloid ex ADHATODA Vasica. Key gradus includit bromination, hydrolysis, et subsequent sal formation cum hydrochloric acidum ad consequi ultima hydrochloride forma. Manufacturers adhaerere ad bonum vestibulum exercitia (GMP) ut princeps puritatis (> XCIX%) et obsequium cum pharmacopopopopein signa (E.G., USP, EP). Advanced analyticae techniques, ut HPLC et NMR, sunt usus ad sanandam structural integritas et constantia de Bromethen Hcl API trans productio batches.
Medicamentum
Clinocally, Bromhexine HCL API indicavit pro Chronic BRONCHITIS, suspiriosis, et alia obstruat pulmonis morbos. Et efficaciam in pediatric et geriatric populationibus fuerit bene documentis, cum dosing moderatur secundum aetatem et renales munus. Recent research etiam elucidat in potential anti-inflammatory et antiviral proprietatibus, praecipue in mitigating Sars-Cov-II-adductus mucus Hyperproduction. Formulationes quibus Bromhexine HCL API sunt saepe combined cum bronchodilators vel antihistamines ad oratio comorbid respiratoriorum symptoms, porro latioring eius medicinales scopum.
Qualis imperium et regulatory obsequio
In global demanda pro bromhexine Hcl API necessitates restrictius qualitas imperium protocols. RELICTUM solventum Analysis, particula mole distribution, et microbial limites sunt rigore monitored ad occursum regulatory guidelines. Stabilitatem studiis sub vario temperatus et humiditas condiciones ensure API retinet potentia per suam pluteo vitae. Regulatory agencies, comprehendo in FDA et EMA, mandate comprehensive documenta de Bromhexine Hcl API scriptor Safetation Profile, comprehendo genotoxicity et pharmacachinitic notitia, inter gentis et pharmacokinetic notitia, ut secure foro probat.
Market dynamics et futura spes
In foro pro Bromhexine HCL API est projected crescere ad Cagr of 4.2% a MMXXIII ad MMXXXX, repulsi ab ortu respiratoriorum morbus invaluisset et augendae genus medicamento productio. Asia-Pacific dominatur API vestibulum cum India et Sina esse clavem exporters. Innovations in hosteined-dimissi formulae et combinatione therapies expectata adhuc elevare in demanda pro bromhexine Hcl API. Tamen, challenges sicut rudis materia et environmental ordinationes ut impulsum productio costs.